SequelSEC

Alzamend Neuro, Inc. ALZN

Pharmaceutical Preparations · CIK 0001677077 · Fiscal year ends 0430

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-04-30
Operating income
-$8.77M
Fiscal year ended 2026-04-30
Free cash flow
Unavailable
Fiscal year ended 2026-04-30

Alzamend Neuro, Inc. (ALZN) reported net income of -$8.77M for the fiscal year ended 2026-04-30. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Alzamend Neuro, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Alzamend Neuro, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$8.77M-$4.50M-$9.94M-$14.87M-$12.32M-$4.95M-$4.42M
Net income-$8.77M-$4.51M-$9.95M-$14.88M-$12.36M-$5.05M-$4.41M
Research & development$3.63M$1.41M$6.46M$7.45M$5.20M$1.31M$1.07M
Weighted-average diluted sharesshares 3.34MUnavailableUnavailableUnavailableshares 89.10MUnavailableUnavailable
Pretax income-$8.77M-$4.51M-$9.95M-$14.88M-$12.36M-$5.05M-$4.41M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.63$-11.32$-132.33$-22.89$-0.14UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.14M$3.08M$3.48M$7.42M$7.12M$3.64M$3.35M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Alzamend Neuro, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-30
Cash & equivalents$710.69K$3.95M$376.05K$5.14M$14.06M$1.93M$90.28K
Total assets$2.08M$4.60M$631.59K$5.92M$14.52M$2.91M$1.81M
Current assets$1.76M$4.18M$455.24K$5.84M$14.41M$2.91M$1.81M
Total liabilities$1.35M$634.76K$3.23M$2.87M$1.16M$899.64KUnavailable
Current liabilitiesUnavailableUnavailableUnavailable$2.87M$1.16M$899.64K$992.31K
Total equity incl. NCI$733.21K$3.97M-$2.59M$3.05M$13.35M$2.01M$821.71K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailable$2.93M$2.87M$1.16M$503.59K$929.64K

Cash flow

Alzamend Neuro, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-30
Operating cash flow-$8.07M-$6.57M-$8.27M-$8.92M-$6.61M-$2.71M-$2.35M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailable-$300.00K-$147.24KUnavailable-$106.46K$100.92K$105.00K
Financing cash flow$4.83M$10.44M$3.65M$200$18.85M$4.45M$2.29M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$707.53K$325.11K$955.63K$3.58M$4.41M$2.03M$1.80M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Alzamend Neuro, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailable12.37x3.24x1.83x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALZN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-10View SEC filing
10-K · Filed 2026-07-22View SEC filing
10-Q · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-12-09View SEC filing
10-Q · Filed 2025-09-10View SEC filing
10-K · Filed 2025-07-22View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.